A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Trial Profile

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Gantenerumab (Primary) ; JNJ 54861911 (Primary) ; Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms DIAN-TU
  • Most Recent Events

    • 30 Oct 2017 According to a Cerveau Technologies media release, the company today announced a research collaboration involving use of its investigational imaging agent (MK-6240) by the international team led by the Dominantly Inherited Alzheimers Network Trial Unit (DIAN-TU) at Washington University School of Medicine in St. Louis in a worldwide clinical trial aimed at finding treatments to prevent Alzheimers disease.
    • 04 Oct 2017 Status changed from active, no longer recruiting to recruiting.
    • 10 Aug 2017 In this trial, one more drug (JNJ-54861911) is added as a test drug and thus number of treatment arms has increased from 4 to 6. Planned no. of patients changed from 394 to 438. Also there is change in study title where cognitive endpoint parameter is added and purpose also modified.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top